secwatch.observer — SEC 8-K summary
======================================

Issuer:     Estrella Immunopharma, Inc. (ESLA)
CIK:        0001844417
Form:       8-K
Filed at:   2025-02-20T23:59:59+00:00
Accession:  0001213900-25-015364
Event type: other_material
Sentiment:  positive
Materiality: 0.60
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Estrella Immunopharma receives Buy rating from D. Boral Capital with $16 price target
--------------------------------------------------------------------------------

- D. Boral Capital initiates coverage on Estrella (ESLA) with a Buy rating and 12-month price target of $16.00 per share.
- Lead candidate EB103, a CD19/CD22-targeted ARTEMIS® T-cell therapy, is in Phase I/II trials for B-cell Non-Hodgkin's Lymphoma.
- D. Boral Capital's valuation model assumes 30% probability of success and a 30% discount rate.
- D. Boral Capital will also provide investment banking services, creating a potential conflict of interest.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1844417/000121390025015364/0001213900-25-015364-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1844417/000121390025015364/ea0231621-8k_estrella.htm
  HTML page:      https://secwatch.observer/filing/0001213900-25-015364

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer